Windham Venture Partners

Total investments

55

Average round size

32M

Portfolio companies

29

Rounds per year

3.06

Lead investments

4

Follow on index

0.47

Exits

3

Stages of investment
SeedEarly Stage VentureLate Stage Venture
Areas of investment
BiotechnologySoftwareAnalyticsInformation TechnologyHealth CareHealth DiagnosticsGeneticsMedical DeviceMedicalBiopharma

Summary

In 2006 was created Windham Venture Partners, which is appeared as VC. The company was established in North America in United States. The main office of represented VC is situated in the New York.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. The fund has no exact preference in some founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Among the various public portfolio startups of the fund, we may underline Neotract, CVRx, Earlens Corporation Among the most successful fund investment fields, there are SaaS, Manufacturing.

The higher amount of exits for fund were in 2019. Opposing the other organizations, this Windham Venture Partners works on 19 percentage points less the average amount of lead investments. The fund is generally included in 2-6 deals every year. The typical startup value when the investment from Windham Venture Partners is 50-100 millions dollars. Deals in the range of 10 - 50 millions dollars are the general things for fund. Considering the real fund results, this VC is 14 percentage points less often commits exit comparing to other organizations. The high activity for fund was in 2019.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Windham Venture Partners, startups are often financed by Versant Ventures, Split Rock Partners, Morgenthaler Ventures. The meaningful sponsors for the fund in investment in the same round are Vertex Ventures HC, Vertex Ventures, Versant Ventures. In the next rounds fund is usually obtained by New Enterprise Associates, Vertex Ventures HC, Versant Ventures.

The current fund was established by Adam Fine, Roger Fine. We also calculated 3 valuable employees in our database.

Show more

Investments analytics

Analytics

Total investments
55
Lead investments
4
Exits
3
Rounds per year
3.06
Follow on index
0.47
Investments by industry
  • Health Care (37)
  • Biotechnology (20)
  • Medical (19)
  • Medical Device (18)
  • Health Diagnostics (13)
  • Show 37 more
Investments by region
  • United States (54)
  • Israel (1)
Peak activity year
2019
Number of Unicorns
1
Number of Decacorns
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
11
Avg. valuation at time of investment
60M
Group Appearance index
0.93
Avg. company exit year
12
Avg. multiplicator
5.83
Strategy success index
0.40

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Personal Genome Diagnostics 04 Jan 2018 Biotechnology, Analytics, Health Diagnostics, Genetics, Medical, Bioinformatics Early Stage Venture 75M United States, Maryland, Baltimore
Valera Health 04 Nov 2021 Analytics, Health Care, Hospital Early Stage Venture 15M United States, New York, New York

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.